

## DAFTAR PUSTAKA

1. Cooper C, Adachi JD, Bardin T, Berenbaum F, Flamion B, Jonsson H, et al. How to define responders in osteoarthritis. *Curr Med Res Opin.* 2013;29:719–29.
2. Hermawan D, Andoko, Kusumaningsih D, Crisanto EY. Pendidikan Kesehatan terhadap Pengetahuan Pasien tentang Osteoarthritis di Puskesmas Kemiling, Bandar Lampung. *Jurnal Kreativitas Pengabdian Kepada Masyarakat.* 2019;2:9–14.
3. Mutiwara E, Najirman N, Afriwardi A. Hubungan Indeks Massa Tubuh dengan Derajat Kerusakan Sendi pada Pasien Osteoarthritis Lutut di RSUP Dr. M. Djamil Padang. *J Kesehat Andalas.* 2016;5:376–80.
4. Honvo G, Reginster JY, Rannou F, Rygaert X, Geerinck A, Rabenda V, et al. Safety of Intra-articular Hyaluronic Acid Injections in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. *Drugs and Aging* 2019;36:101–27.
5. Pratiwi AI. Diagnosis and treatment. *J Major.* 2015;4:11-16.
6. Lapane KL, Yang S. Effects of prescription non-steroidal anti-inflammatory agents on symptoms and disease progression among patients with knee osteoarthritis. *Arthritis Rheumatol Author manuscript; available PMC* 2016 March 01. 2008;23:1–7.
7. Waranugraha Y, Pratomo B, Studi P, Dokter P, Kedokteran F, Brawijaya U, et al. Hubungan Pola Penggunaan OAINS dengan Gejala Klinis Gastropati pada Pasien Reumatik Relationship of NSAID Utilization Pattern With Gastropathy Symptoms in Rheumatic Patient. *J Kedokt Brawijaya.* 2010;26:107–12.
8. Zahra AP, Carolia N. Obat Antiinflamasi Non-steroid (OAINS): Gastroprotektif vs Kardiotoxik. *Majority.* 2017;6:153–8.

9. Mardhiyah R, Fauzi A, Syam AF. Diagnosis dan Tata Laksana Enteropati akibat Obat Anti Inflamasi Non Steroid (OAINS). *J Penyakit Dalam Indones*. 2017;2:190.
10. Perhimpunan Reumatologi Indonesia. Penggunaan Obat Anti Inflamasi Non Steroid. *Perhimpun Reumatol Indones*. 2014;16.
11. K Marcellus Simadibrata, Makmun D, Abdullah M, Syam AF, Fauzi A, Renaldi K et al. Konsensus nasional penatalaksanaan dispepsia dan infeksi *Helicobacter pylori*. *Konsensus Nasional Penatalaksanaan Dispepsia dan Infeksi Helicobacter pylori*. 2014. 16
12. Shetty AJ, Balaraju G, Shetty S, Pai CG. Quality of life in dyspepsia and its subgroups using EQ-5D (EuroQol) questionnaire. *Saudi J Gastroenterol*. 2017;23:112–6.
13. Fithriyana R. Faktor-Faktor Yang Berhubungan Dengan Kejadian Dispepsia Pada Pasien Di Wilayah Kerja Puskesmas Bangkinang Kota. *PREPOTIF J Kesehat Masy*. 2018;2:43–54.
14. Andre Y, Machmud R, Murni AW. Hubungan Pola Makan dengan Kejadian Depresi pada Penderita Dispepsia Fungsional. *J Kesehat Andalas*. 2013;2:73.
15. Gusriadi AR. Gambaran Varian Gen CYP2C9 rs1799853 pada Pasien Arthritis Etnik Minangkabau yang Mempunyai Efek Samping pada Saluran Cerna Akibat Penggunaan OAINS [Skripsi]. Padang:Universitas Andalas;2019.
16. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. *Gastroenterology*. 2001;120:594–606.
17. Hollenz M, Stolte M, Leodolter A, Labenz J. NSAID-associated dyspepsia and ulcers: A prospective cohort study in primary care. *Dig Dis*. 2006;24:189–94.
18. Bruyère O, Cooper C, Arden N, Branco J, Brandi ML, Herrero-Beaumont G, et al. Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Epidemiology and Phenotype

of Osteoarthritis. *Drugs and Aging*. 2015;32:179–87.

19. T. N. The Epidemiology and Impact of Pain in Osteoarthritis. *Osteoarthr Cartil*. 2014;21:1145–53.
20. Kemenkes RI. Laporan Nasional Riset Kesehatan Dasar. Kementerian Kesehatan RI. 2018;1–582.
21. He Y, Li Z, Alexander PG, Ocasio-Nieves BD, Yocum L, Lin H, et al. Pathogenesis of osteoarthritis: Risk factors, regulatory pathways in chondrocytes, and experimental models. *Biology (Basel)*. 2020;9:1–32.
22. Bliddal H, Leeds AR, Christensen R. Osteoarthritis, obesity and weight loss: Evidence, hypotheses and horizons - a scoping review. *Obes Rev*. 2014;15:578–86.
23. Walter SS, Wintermeyer E, Klinger C, Lorbeer R, Rathmann W, Peters A, et al. Association between metabolic syndrome and hip osteoarthritis in middle-aged men and women from the general population. *Plos One*. 2020;15:1–13.
24. Chen L, Zheng JJY, Li G, Yuan J, Ebert JR, Li H, et al. Pathogenesis and clinical management of obesity-related knee osteoarthritis: Impact of mechanical loading. *J Orthop Transl*. 2020;24:66–75.
25. Palazzo C, Nguyen C, Lefevre-Colau MM, Rannou F, Poiraudau S. Risk factors and burden of osteoarthritis. *Annals of Phys Rehabil Med*. 2016;59:134–8.
26. Nakata K, Hanai T, Take Y, Osada T, Tsuchiya T, Shima D, et al. Disease-modifying effects of COX-2 selective inhibitors and non-selective NSAIDs in osteoarthritis: a systematic review. *Osteoarthr Cartil*. 2018;26:1263–73.
27. Krasnokutsky S, Attur M, Palmer G, Samuels J, Abramson SB. Current concepts in the pathogenesis of osteoarthritis. *Osteoarthr and Cartil*. 2008;16:6–8.
28. Knorth H, Dorfmueller P, Lebert R, Schmidt WE, Wittenberg RH, Heukamp

- M, et al. Participation of cyclooxygenase-1 in prostaglandin E2 release from synovitis tissue in primary osteoarthritis in vitro. *Osteoarthr Cartil.* 2004;12:658–66.
29. Putra A, Nurmalasari Y, Anita T. Gambaran Klinis Osteoarthritis Primer pada Usia 40-60 pada Laki-Laki dan Perempuan di RSUD Dr. H. Abdul Moeloek Provinsi Lampung Tahun 2018. *J Ilmu Kedokt Dan Kesehatan*, Vol 5, Nomor 3, Juli 2018 189. 2018;18:1–4.
30. Winangun W. Diagnosis Dan Tatalaksana Komprehensif Osteoarthritis. *J Kedokt.* 2019;5:125.
31. Perhimpunan Reumatologi Indonesia. Rekomendasi IRA untuk Diagnosis dan Penatalaksanaan Osteoarthritis. Divisi Reumatologi Departemen Ilmu Penyakit Dalam FKUI/RSCM. 2014. 1–3.
32. Ickinger C, Tikly M. Current approach to diagnosis and management of osteoarthritis. *South African Fam Pract.* 2010;52:382–90.
33. Imananta FP, Sulistyaningsih. Artikel Tinjauan: Penggunaan NSAIDs (Nonsteroidal Anti Inflammation Drugs) Menginduksi Peningkatan Tekanan Darah pada Pasien Arthritis. *Farmaka.* 2018;16:72–9.
34. Conaghan PG. A turbulent decade for NSAIDs: Update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. *Rheumatol Int.* 2012;32:1491–502.
35. Sinha M, Gautam L, Shukla PK, Kaur P, Sharma S, Singh TP. Current Perspectives in NSAID-Induced Gastropathy. 2013;2013.
36. Fajriani F. Pemberian Obat-Obatan Anti Inflamasi Non Steroid (AINS) pada Anak. *J Dent Indones.* 2008;15:200–4.
37. Morita I. Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat. 2002;68–69:165–75.
38. Pountos I, Georgouli T, Bird H, Giannoudis P V. Nonsteroidal anti-inflammatory drugs: Prostaglandins, indications, and side effects. *Int J Interf*



- Cytokine Mediat Res. 2011;3:19–27.
39. Perkumpulan Gastroenterologi Indonesia. Konsensus Nasional 2011 Penatalaksanaan Gastro-enteropati OAINS. *Papdi*. 2011;1–26.
  40. Rachmawati E, Setia Pratama P, Machlaurin A. Studi Penggunaan Obat Pada Pasien Osteoarthritis Usia Lanjut di Instalasi Rawat Jalan Rumah Sakit dr. H Koesnadi Bondowoso Tahun 2013. *e-Jurnal Pustaka Kesehatan*. 2018;6:408–15.
  41. Katzung BG, Masters SB, Trevor AJ. *Farmakologi Dasar & Klinik Edisi 12*. Vol. 53, *Journal of Chemical Information and Modeling*. 2013. 1689–1699.
  42. Bushra R, Aslam N. An overview of clinical pharmacology of ibuprofen. *Oman Med J*. 2010;25:155–61.
  43. Nair B, Taylor-Gjevre R. A review of topical diclofenac use in musculoskeletal disease. *Pharmaceuticals*. 2010;3:1892–908.
  44. Kołodziejaska J, Kołodziejczyk M. Diclofenac in the treatment of pain in patients with rheumatic diseases. *Reumatologia*. 2018;56:174–83.
  45. Parhan, Gulo AY. Pengaruh Kecepatan Pembentukan Tukak Lambung Terhadap Pemberian Berbagai Golongan NSAID Pada Tikus Jantan. *J Farm*. 2019;1:15.
  46. Datta N, Pal M, Roy U, Mitra R, Pradhan A. Mefenamic Acid Prodrugs and Codrugs - Two Decades of Development. *World J Pharm Res*. 2014;13:15.
  47. Wahyuningsih, M.Si., Apt I, Widyarningsih W, Wulandari S. Reduced Ulcerogenicity From Self-Nano Emulsifying Drug Delivery System of Piroxicam. *Pharmaciana*. 2018;8:248.
  48. Interactions TIE of ADR and. *Meyler's Side Effects of Drugs (Fifteenth Edition)*. 2006;2843–5.
  49. Chyka PA, Erdman AR, Christianson G, Wax PM, Booze LL, Manoguerra AS, et al. Salicylate poisoning: An evidence-based consensus guideline for out-of-hospital management. *Clin Toxicol*. 2007;45:95–131.

50. Talley NJ, Vakil N. Guidelines for the management of dyspepsia. *Am J Gastroenterol*. 2005;100:2324–37.
51. Hemriyantton B, Arifin H, Murni AW. Hubungan Depresi Terhadap Tingkat Kepatuhan dan Kualitas Hidup Pasien Sindrom Dispepsia di RSUP Dr. M. Djamil Padang. *J Sains Farm Klin*. 2017;3:141.
52. Ari S. Faktor-Faktor Yang Berhubungan Dengan Kejadian Dyspepsia Pada Remaja Di Wilayah Kerja Puskesmas Krueng Barona Jaya Kabupaten Aceh Besar Tahun 2019. *Biot J Ilm Biol Teknol dan Kependidikan*. 2020;8:119.
53. Andora N, Atikah SN. Hubungan Pola Makan Dan Stres Dengan Kejadian Dispepsia Di Puskesmas Blambangan Kecamatan Blambangan Pagar Kabupaten Lampung Utara Tahun 2018. 2020;1.
54. Oustamanolakis P, Tack J. Dyspepsia: Organic versus functional. *J Clin Gastroenterol*. 2012;46:175–90.
55. Functional A, Functional B. Appendix B: Rome III Diagnostic Criteria for Functional Gastrointestinal Disorders. *The Am J Gastroenterol*. 2010;105:798–801.
56. Derrick; Franfy; Wirawan D. Acute Pancreatitis - Etiology, Pathogenesis, Pathophysiology and The Current Trend in Its Management and Prevention. *Indones J Gastroenterol Hepatol Dig Endosc*. 2019;20:27–37.
57. Jalil M, Aslam F, Bhatti TK, Umar M, Khaar HB. Dyspepsia in Cirrhotic Hepatitis C Patients. 2017;21:321–4.
58. Halder SLS, Locke GR, Schleck CD, Zinsmeister AR, Talley NJ. Influence of alcohol consumption on IBS and dyspepsia. *Neurogastroenterol Motil*. 2006;18:1001–8.
59. Spiller RC. Dyspepsia in pregnancy. *Curr Obstet Gynaecol*. 2001;2:38–45.
60. Bacci MR, Chehter EZ. Dyspepsia among patients with chronic kidney disease: A cross sectional study. *Int Arch Med*. 2013;6:1.
61. Amrulloh FM, Utami N. Hubungan Konsumsi OAINS terhadap Gastritis

- The Relation of NSAID Consumption to Gastritis. *Majority*. 2016;5:18–21.
62. Bonetto S, Gruden G, Beccuti G, Ferro A, Saracco GM, Pellicano R. Management of Dyspepsia and Gastroparesis in Patients with Diabetes. A Clinical Point of View in the Year 2021. *J Clin Med*. 2021;10:1313.
63. Maser C, Toset A, Roman S. Gastrointestinal manifestations of endocrine disease. *World J Gastroenterol*. 2006;12:3174–9.
64. Prasetyo Muhammad E, Widya Murni A, Sulastri D, Miro S. Hubungan Derajat Keasaman Cairan Lambung dengan Derajat Dispepsia pada Pasien Dispepsia Fungsional. *J Kesehat Andalas*. 2016;5:371–5.
65. Zagari RM, Law GR, Fuccio L, Cennamo V, Gilthorpe MS, Forman D, et al. Epidemiology of Functional Dyspepsia and Subgroups in the Italian General Population: An Endoscopic Study. *Gastroenterology*. 2010;138:1302–11.
66. Murni AW. Kadar Kortisol Plasma pada Dispepsia Fungsional dengan Gangguan Psikosomatik. *J Penyakit Dalam Indones*. 2020;7:15.
67. Nadiaskara SN. Pengaruh Zikir Qalbu terhadap Skor DASS-21 (Depression Anxiety Stress Scale-21) Mahasiswa Tahun Ketiga Profesi Dokter Fakultas Kedokteran Universitas Andalas [Skripsi]. Padang:Universitas Andalas;2019.
68. Risnomarta SD, Arnelis A, Ernawati E. Hubungan OAINS pada Pengobatan Dismenorea dengan Kejadian Dispepsia pada Mahasiswi Fakultas Kedokteran Universitas Andalas. *J Kesehat Andalas*. 2015;4:415–20.
69. Straus WL, Ofman JJ, MacLean C, Morton S, Berger ML, Roth EA, et al. Do NSAIDs cause dyspepsia? A meta-analysis evaluating alternative dyspepsia definitions. *Am J Gastroenterol*. 2002;97:1951–8.
70. Yusup F. Uji Validitas dan Reliabilitas. *J Tarb J Ilm Kependidikan*. 2018;7:17–23.
71. Haq I, Murphy E, Dacre J. Review: Osteoarthritis. *Postgrad Med J*. 2003;79:377–83.

72. Gustina E, Handani MC, Sirait A. Studi Kasus Kontrol di Rumah Sakit Tk. II Putri Hijau Medan Tahun 2017 American College of Rheumatology sebagai sekelompok kondisi heterogen yang Berdasarkan data Badan Kesehatan Dunia (WHO), penduduk yang mengalami. *J Mitrahusada*. 2020;3:88–103.
73. Sasono B, Amanda NA, Dewi DNSS. Faktor Dominan pada Penderita Osteoarthritis di RSUD dr. Mohamad Soewandhie, Surabaya, Indonesia. *J Med Udayana*. 2020;9:3–8.
74. Etikasari R, Murharyanti R. Hubungan Rasionalitas Penggunaan Obat Anti Inflamasi Non Steroid Dengan Derajat Osteoarthritis Pada Pasien Usia Lanjut. *Indones J*. 2020;4:19–23.
75. Magni A, Agostoni P, Bonezzi C, Massazza G, Menè P, Savarino V, et al. Management of Osteoarthritis: Expert Opinion on NSAIDs. *Pain Ther*. 2021;10:783–808.
76. Valle JD. Peptic Ulcer Disease and Related Disorders. *Harrison's Princ Intern Med 16<sup>th</sup> ed*. USA: McGraw Hill; 2005. 1746-1756.
77. MN Hutapea. Perbedaan Kejadian Dispepsia antara Pengguna Obat Antiinflamasi Non Steroid (OAINS) dan Bukan Pengguna Obat Antiinflamasi Non Steroid (OAINS) di RSUP. Haji Adam Malik Medan Tahun 2017 [Skripsi]. Medan; Universitas Sumatera Utara; 2019.
78. Andriansyah FF. Hubungan antara Usia, Jenis Kelamin dan Lama Penggunaan OAINS pada Pasien Osteoarthritis terhadap Kejadian Dispepsia di RS. Bhakti Yudha Depok Periode 01 Januari-31 Desember 2009 [Skripsi]. Jakarta; UPN Veteran Jakarta; 2009.